Share this

Cancer Research in Scotland

The Cancer Network supports a wide range of clinical studies which are helping to progress cancer care in Scotland and beyond, and all Scottish research ongoing within the network is registered with the National Institute of Health Research (NIHR).

The cancer clinical trial portfolio is very dynamic and is frequently changing as studies open and close to recruitment. Across Scotland, there is a wide range of clinical trials happening in different disease sites. Information on trials happening in the UK can be found on the Be Part of Research platform and the Cancer Research UK website. For specific information on trials happening in Scotland please contact your cancer professional or your local cancer research network.

To highlight the clinical trials happening in Scotland the cancer research network will feature current trials happening during the different cancer awareness months that take place throughout the year.

 

MAY: BLADDER CANCER AND SKIN/SUN AWARENESS MONTH

 

BLADDER CANCER

Bladder cancer begins in the lining of the bladder. The bladder is part of the urinary system, which filters waste products out of your blood and makes urine.

It is the ninth most common cancer diagnosed worldwide and around 10,300 people are diagnosed with bladder cancer every year in the UK. Generally more men than women get bladder cancer and it is usually more common in those over 60 years of age.

For more information on bladder cancer please visit Cancer Research UK or Action Bladder Cancer UK.

 

Trial Spotlight

KEYNOTE-676

This study will evaluate how well an investigational study drug called pembrolizumab works to treat high-risk, non-muscle invasive bladder cancer when combined with Bacillus Calmette-Guerin (BCG) vs BCG alone.

BCG is a vaccine for tuberculosis (TB) but it is also very good at helping to stop or delay bladder cancers growing back or spreading into the deeper layers of the bladder. It seems to encourage cells of the immune system to grow and become very active in the bladder lining and these cells may kill off any cancer cells that might grow back or have been left behind.

This study is currently recruiting in Inverness

 

KEYNOTE-866

This study aims to test the safety of the drug pembrolizumab in combination with chemotherapy and surgery. It also aims to see how well the body manages pembrolizumab and hopes to determine if it helps patients have a better quality of life and live longer. This study is for people who have muscle-invasive bladder cancer (MIBC). 

 This study is currently recruiting in Aberdeen.

 

VIXEN

The trial hopes to develop new methods for diagnosing bladder cancer. Current methods for detecting bladder cancer are very effective for more obvious changes but are not very sensitive for early and subtle changes, or for deep lying cancers. The purpose of this trial is to evaluate the function and accuracy of a new diagnostic system for detecting bladder cancer related biomarker mRNAs from the left-over urine.

This study is currently recruiting in Dundee

 

SKIN CANCER

Skin cancer includes basal cell skin cancer, squamous cell skin cancers, and other rarer types. These cancers occur in the epidermis layer of the skin. Melanoma is the 5th most common cancer in the UK and is the most aggressive form of the disease. It develops from damage to the skin cells called melanocytes which are in the deeper layers of the epidermis.

Skin cancer tends to develop most often on skin that has been exposed to the sun and it is important to check your skin regularly and see a doctor if any changes occur.

For more information on skin cancers please visit the Cancer Research UK website.

 

Trial Spotlight

DANTE

Is a randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma. It is for patients with advanced melanoma that has spread to the lymph nodes.

The objectives of the trial are to see if it stops the progression of the disease, assess the tumour’s response to the treatment and look at overall survival rates.

The trial is currently recruiting Aberdeen, Inverness, Dundee and Glasgow.